Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon.....»»

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
14-day Study of PTI-801, Company's Third Generation Corrector, in CF Patients on Background Orkambi® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces Additional Study of PTI-428 in CF.....»»
Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update
Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million Forms Strategic Bispecific Antibody Partnership with Alligator Bioscience Demonstrating Versatility of the ADAPTIR™ Technology Platform Advances Multiple AD.....»»
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass., March .....»»
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a .....»»
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expe.....»»
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter .....»»
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:G.....»»
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today repor.....»»
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 201.....»»
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business updat.....»»
Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights
- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), .....»»
Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update
Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual Property Portfol.....»»
Net Element Reports Full-Year 2017 Financial Results and Provides Business Update
Net Element Reports Full-Year 2017 Financial Results and Provides Business Update.....»»
SANUWAVE Health Reports 2017 Financial Results and Provides a Business Update
SANUWAVE Health Reports 2017 Financial Results and Provides a Business Update.....»»
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
-- Initiated URIROX-1™, First Phase.....»»
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it.....»»
Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update
Company to host webcast and conference call on Tuesday, March 20, 2018 at 8 am ET Management to discuss recent data and progress on development plans WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. ("Eloxx") .....»»
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene th.....»»
OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update.....»»
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update.....»»